Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti - Drug Resistance Updates, 2021 - Elsevier
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Human prostate cancer risk factors

DG Bostwick, HB Burke, D Djakiew… - … Journal of the …, 2004 - Wiley Online Library
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with
similar likelihood of neoplastic foci found within the prostates of men around the world …

Mitosis-targeted anti-cancer therapies: where they stand

KS Chan, CG Koh, HY Li - Cell death & disease, 2012 - nature.com
The strategy of clinically targeting cancerous cells at their most vulnerable state during
mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the …

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale

E Komlodi-Pasztor, DL Sackett, AT Fojo - Clinical Cancer Research, 2012 - AACR
Although they have been advocated with an understandable enthusiasm, mitosis-specific
agents such as inhibitors of mitotic kinases and kinesin spindle protein have not been …

Microtubule-targeting drugs: more than antimitotics

R Kaul, AL Risinger, SL Mooberry - Journal of natural products, 2019 - ACS Publications
Nature has yielded numerous compounds that bind to tubulin/microtubules and disrupt
microtubule function. Even with the advent of targeted therapies for cancer, natural products …

Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia

G Kövesi, B Szende - Oncology, 2003 - karger.com
Introduction: Leukoplakia is the most frequent pre-blastomatous alteration in the oral cavity.
Its potential for malignant transformation is unpredictable. The aim of the present study was …

Cell proliferation and apoptosis in prostate tumors and adjacent non‐malignant prostate tissue in patients at different time‐points after castration treatment

N Ohlson, P Wikström, P Stattin, A Bergh - The prostate, 2005 - Wiley Online Library
Background Androgen ablation is the standard treatment for advanced prostate cancer but
the short‐term cellular effects are largely unknown. Methods Sextant prostate biopsies were …

Epithelial cell, keratocyte, and endothelial cell apoptosis in Fuchs' dystrophy and in pseudophakic bullous keratopathy

N Szentmary, B Szende… - European journal of …, 2005 - journals.sagepub.com
Purpose To elucidate the pathomechanism of Fuchs' dystrophy and pseudophakic bullous
keratopathy (PBK) by examining cell apoptosis in different corneal layers. Methods The …

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies

FF Lang, MR Gilbert, VK Puduvalli, J Weinberg… - Neuro …, 2002 - academic.oup.com
Although no optimal treatment is currently available for malignant brain tumors, as the
molecular mechanisms underlying brain tumor development have been delineated, new …

Early effects of pharmacological androgen deprivation in human prostate cancer

M Mercader, S Sengupta, BK Bodner… - BJU …, 2007 - Wiley Online Library
OBJECTIVES To assess the early histological effects of pharmacological androgen
deprivation (AD), which have been assessed only over longer periods, as surgical castration …